EnsoData Raises $20M in Series B to Revolutionize AI-Driven Diagnostics in Sleep Medicine and Beyond

EnsoData is thrilled to announce that it has successfully raised $20,000,000 in its latest funding round, marking a significant milestone for the company as it continues to drive innovation in healthcare diagnostics. Over the past eight years, EnsoData has been at the forefront of harnessing artificial intelligence and machine learning to transform sleep medicine and broader healthcare practices. Its groundbreaking platform, EnsoSleep, has already set industry benchmarks by leveraging AI to streamline and enhance the diagnosis of sleep disorders. Initially cleared by the FDA in 2017 for diagnostic analysis of in-lab sleep studies, EnsoSleep expanded its capabilities in 2021 to include home studies, providing clinicians with a sophisticated, editing, and reporting tool that also measures total sleep time. The latest advance, EnsoSleep PPG, further solidifies EnsoData’s commitment to accessible and cost-effective healthcare solutions by converting FDA-cleared pulse oximetry technology into a powerful diagnostic asset. FDA clearance for EnsoSleep PPG in February 2024 has opened new avenues for clinicians, enabling them to reach patients more efficiently through AI-driven analyses that use widely available wearable devices. This new infusion of capital is poised to accelerate EnsoData’s research and development efforts as the company continues to expand its suite of revolutionary AI tools. With a mission to reduce healthcare turnaround times, alleviate patient backlogs, and ultimately enhance patient outcomes, EnsoData is perfectly positioned to usher in a new era of rapid and accurate diagnoses. This funding not only validates the company’s innovative approach but also reinforces its commitment to addressing some of the biggest challenges in human health through advanced technology.